After H.C. Wainwright and Raymond James gave uniQure (NASDAQ: QURE) a Buy rating last month, the company received another Buy, this time from Mizuho Securities. Analyst Uy Ear maintained a Buy rating on uniQure yesterday and set a price target of $52.00. The company’s shares closed last Thursday at $19.39, close to its 52-week low of $18.70.
According to TipRanks.com, Ear is a 1-star analyst with an average return of -11.4% and a 16.7% success rate. Ear covers the Healthcare sector, focusing on stocks such as Arcutis Biotherapeutics, Sarepta Therapeutics, and Avrobio.
uniQure has an analyst consensus of Strong Buy, with a price target consensus of $58.29.
See the top stocks recommended by analysts >>
uniQure’s market cap is currently $913.2M and has a P/E ratio of 2.84.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington’s disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.
Read More on QURE:
- B.Riley Financial Sticks to Their Buy Rating for Journey Medical Corp (DERM)
- Morgan Stanley Pounds the Table on Tesla Stock
- Needham Maintains a Hold Rating on Cardiovascular Systems (CSII)
- Credit Suisse Reaffirms Their Sell Rating on Deutsche Bank AG (DB)
- Mizuho Securities Remains a Buy on Gilead Sciences (GILD)
